In this study, the authors showed that CD1b expression is associated with a better prognosis in Lung Adenocarcinoma (LUAD) and promotes anti-tumor immunity by constructing a TMB prognostic model that effectively predicts the prognosis of patients with LUAD, which can be used as a potential prognostic biomarker and immune-related therapeutic target for LUAD (Li et al., 2022). Here, CD1B is linked to lung adenocarcinoma.